Repurposing Amiloride into Breast Cancer Drugs with a Dual-Targeting Mechanism

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1100432

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project aims to transform a diuretic drug (amiloride) into a breast cancer drug that acts via a novel molecular mechanism. The science of medicinal chemistry will be used to remove amiloride's diuretic effects whilst gaining potent dual-activity against two breast cancer targets, uPA and NHE1. Our study will validate a new pharmacological approach in cancer treatment and produce patented drugs suitable for development into first-in-class breast cancer drugs.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $611,966.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medicinal and Biomolecular Chemistry not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | drug design | drug discovery | medicinal chemistry | molecular pharmacology

Related Links